TRX319 / Tr1X - LARVOL DELTA

Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis… (Yahoo Finance) - "On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026."

IND • New P1/2 trial • Multiple Sclerosis

Tr1X Announces…$50 Million in Additional Financing (Yahoo Finance) - "...Allowing Tr1X to advance the TRX319 Phase 1/2a study and the ongoing TRX103 Phase 1/2a trial for patients with refractory Crohn’s disease."

Financing • Crohn's disease • Multiple Sclerosis